FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891647981> ?p ?o ?g. }

• W2891647981 endingPage "1765" @default.
• W2891647981 startingPage "1765" @default.
• W2891647981 abstract "Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types.Theoretically, the high-energy emission of short-range alpha particles causes complex double-stranded DNA breaks, eliciting cell death. No known resistance mechanism to alpha particles has been reported or scientifically established. The short-range emission of alpha particle radiation confines its cytotoxic effect to cancerous lesions and the surrounding tumor microenvironment while limiting toxic effects to noncancerous tissues. The high level of radiobiological effectiveness of alpha particles, in comparison with beta emissions, requires fewer particle tracks to induce cell death. Clinically effective alpha particle-emitting isotopes for cancer therapy should have a short half-life, which will limit long-term radiation exposure and allow for the production, preparation, and administration of these isotopes for clinical use and application. Radium 223 dichloride is the first-in-class, commercially available targeted alpha therapy approved for the treatment of patients with metastatic castration-resistant prostate cancer with bone metastases. Given the established overall survival benefit conferred by radium 223 for patients with metastatic castration-resistant prostate cancer, several other targeted alpha therapies are being investigated in clinical trials across many tumor types.Targeted alpha therapy represents an emerging treatment approach and provides for the possibility to bypass mechanisms of acquired resistance in selected tumors. In addition, developing novel radionuclide conjugation strategies may overcome targeting limitations. So far, the clinical success of radium 223 has demonstrated the proof of concept for targeted alpha therapy, and future studies may lead to additional treatment options for many cancer types." @default.
• W2891647981 created "2018-09-27" @default.
• W2891647981 creator A5005310278 @default.
• W2891647981 creator A5010863711 @default.
• W2891647981 creator A5014159559 @default.
• W2891647981 creator A5030716470 @default.
• W2891647981 creator A5036543091 @default.
• W2891647981 creator A5043648973 @default.
• W2891647981 creator A5046292225 @default.
• W2891647981 creator A5053749991 @default.
• W2891647981 creator A5088518998 @default.
• W2891647981 date "2018-12-01" @default.
• W2891647981 modified "2023-10-10" @default.
• W2891647981 title "Targeted Alpha Therapy, an Emerging Class of Cancer Agents" @default.
• W2891647981 cites W1532568685 @default.
• W2891647981 cites W1979624352 @default.
• W2891647981 cites W1980796692 @default.
• W2891647981 cites W1983514189 @default.
• W2891647981 cites W1986961751 @default.
• W2891647981 cites W1993575340 @default.
• W2891647981 cites W1997928845 @default.
• W2891647981 cites W2010233571 @default.
• W2891647981 cites W2014132187 @default.
• W2891647981 cites W2018649196 @default.
• W2891647981 cites W2028387248 @default.
• W2891647981 cites W2042548235 @default.
• W2891647981 cites W2059383202 @default.
• W2891647981 cites W2063548091 @default.
• W2891647981 cites W2080585386 @default.
• W2891647981 cites W2088799733 @default.
• W2891647981 cites W2094108414 @default.
• W2891647981 cites W2105074988 @default.
• W2891647981 cites W2106946113 @default.
• W2891647981 cites W2122878067 @default.
• W2891647981 cites W2125047406 @default.
• W2891647981 cites W2141454098 @default.
• W2891647981 cites W2143818728 @default.
• W2891647981 cites W2147376175 @default.
• W2891647981 cites W2149171028 @default.
• W2891647981 cites W2266928747 @default.
• W2891647981 cites W2346497885 @default.
• W2891647981 cites W2467018059 @default.
• W2891647981 cites W2483834070 @default.
• W2891647981 cites W2511660718 @default.
• W2891647981 cites W2550547159 @default.
• W2891647981 cites W2568078552 @default.
• W2891647981 cites W2573369749 @default.
• W2891647981 cites W2604062834 @default.
• W2891647981 cites W2606187374 @default.
• W2891647981 cites W2731366479 @default.
• W2891647981 cites W2735160137 @default.
• W2891647981 cites W2755508849 @default.
• W2891647981 cites W2762046908 @default.
• W2891647981 cites W2767227550 @default.
• W2891647981 cites W2768888111 @default.
• W2891647981 cites W4239355212 @default.
• W2891647981 cites W4244010490 @default.
• W2891647981 doi "https://doi.org/10.1001/jamaoncol.2018.4044" @default.
• W2891647981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30326033" @default.
• W2891647981 hasPublicationYear "2018" @default.
• W2891647981 type Work @default.
• W2891647981 sameAs 2891647981 @default.
• W2891647981 citedByCount "122" @default.
• W2891647981 countsByYear W28916479812019 @default.
• W2891647981 countsByYear W28916479812020 @default.
• W2891647981 countsByYear W28916479812021 @default.
• W2891647981 countsByYear W28916479812022 @default.
• W2891647981 countsByYear W28916479812023 @default.
• W2891647981 crossrefType "journal-article" @default.
• W2891647981 hasAuthorship W2891647981A5005310278 @default.
• W2891647981 hasAuthorship W2891647981A5010863711 @default.
• W2891647981 hasAuthorship W2891647981A5014159559 @default.
• W2891647981 hasAuthorship W2891647981A5030716470 @default.
• W2891647981 hasAuthorship W2891647981A5036543091 @default.
• W2891647981 hasAuthorship W2891647981A5043648973 @default.
• W2891647981 hasAuthorship W2891647981A5046292225 @default.
• W2891647981 hasAuthorship W2891647981A5053749991 @default.
• W2891647981 hasAuthorship W2891647981A5088518998 @default.
• W2891647981 hasConcept C121332964 @default.
• W2891647981 hasConcept C121608353 @default.
• W2891647981 hasConcept C126322002 @default.
• W2891647981 hasConcept C143998085 @default.
• W2891647981 hasConcept C184779094 @default.
• W2891647981 hasConcept C2777783956 @default.
• W2891647981 hasConcept C2780192828 @default.
• W2891647981 hasConcept C2780737065 @default.
• W2891647981 hasConcept C2781230642 @default.
• W2891647981 hasConcept C502942594 @default.
• W2891647981 hasConcept C509974204 @default.
• W2891647981 hasConcept C535046627 @default.
• W2891647981 hasConcept C58962609 @default.
• W2891647981 hasConcept C66385817 @default.
• W2891647981 hasConcept C71924100 @default.
• W2891647981 hasConcept C96232424 @default.
• W2891647981 hasConceptScore W2891647981C121332964 @default.
• W2891647981 hasConceptScore W2891647981C121608353 @default.
• W2891647981 hasConceptScore W2891647981C126322002 @default.
• W2891647981 hasConceptScore W2891647981C143998085 @default.

• next